A Double-Blind, Placebo-Controlled Trial of Dexmethylphenidate Hydrochloride and d,l-threo-Methylphenidate Hydrochloride in Children With Attention-Deficit/Hyperactivity Disorder

Add time:08/02/2019    Source:sciencedirect.com

ABSTRACTObjective:To evaluate the efficacy and safety of dexmethylphenidate hydrochloride (d-MPH, Focalin™) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and to test an a priori hypothesis that d-MPH would have a longer duration of action than d,l-threo-methylphenidate (d,l-MPH).

We also recommend Trading Suppliers and Manufacturers of D-THREO-METHYLPHENIDATE HYDROCHLORIDE (cas 19262-68-1). Pls Click Website Link as below: cas 19262-68-1 suppliers

Prev:Comparative Pharmacodynamics and Plasma Concentrations of D-THREO-METHYLPHENIDATE HYDROCHLORIDE (cas 19262-68-1) After Single Doses of D-THREO-METHYLPHENIDATE HYDROCHLORIDE (cas 19262-68-1) and d,l-threo-Methylphenidate Hydrochloride in a Double-Blind, Placebo-Controlled, Crossover Laboratory School Study in Children With Attention-Deficit/Hyperactivity Disorder
Next:Binding of d-threo-[11C]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine)